drugset / Trial / NCT03143270
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Phase 0
Active not recruiting
20 enrolled
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.
Timeline
- Start
- 2017-04-28
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |